Goldman Sachs Group initiated coverage on shares of Turning Point Therapeutics (NASDAQ:TPTX) in a research report report published on Monday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $50.00 price objective on the stock.
Separately, Wells Fargo & Co started coverage on shares of Turning Point Therapeutics in a report on Monday. They set an outperform rating and a $53.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, Turning Point Therapeutics has a consensus rating of Buy and a consensus price target of $47.17.
NASDAQ:TPTX opened at $30.26 on Monday. Turning Point Therapeutics has a twelve month low of $24.21 and a twelve month high of $38.00.
In other Turning Point Therapeutics news, CEO Athena Countouriotis bought 12,000 shares of Turning Point Therapeutics stock in a transaction that occurred on Monday, April 22nd. The shares were acquired at an average price of $18.00 per share, for a total transaction of $216,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Brian Lee Baker bought 2,800 shares of Turning Point Therapeutics stock in a transaction that occurred on Monday, April 22nd. The shares were acquired at an average price of $18.00 per share, for a total transaction of $50,400.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 774,800 shares of company stock worth $13,946,400 in the last 90 days.
About Turning Point Therapeutics
Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.